Novo Nordisk Jobs and Investments – Athlone
Established: Novo Nordisk are a global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark. Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes care medications and devices. Its main product is the drug semaglutide, used to treat diabetes under the brand name Ozempic and obesity under the brand name Wegovy.
Jobs and Investment: In December 2023, Novo Nordisk announced that they bought a manufacturing plant in Athlone to expand their manufacturing capacity to meet worldwide demand. Novo Nordisk paid €85 million to acquire the former Elan Drug Technologies plant from Irish-headquartered pharma group Alkermes. The transaction is expected to close in mid-2024. The acquisition of the Athlone facility represents an expansion of Novo Nordisk’s global manufacturing setup and will provide Novo Nordisk with additional development and manufacturing capacity for current and future oral products. With this acquisition, Novo will welcome 400 highly skilled Alkermes employees, equipped with valuable expertise in oral drug development and manufacturing.